Stephens & Co. Reiterates Overweight on Nurix Therapeutics, Maintains $31 Price Target

Benzinga · 10/14 13:02
Stephens & Co. analyst Sudan Loganathan reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and maintains $31 price target.